Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • Topics
  • Dermatology
  • Cardiovascular
  • Diabetes
  • GI
  • HIV/AIDS
  • Photoclinic
  • Quiz
  • Special Report
  • Image IQ
MJH Life Sciences

SUBSCRIBE: eNewsletter

After Metformin, which Class Would you Choose?
After metformin which class of drugs do you use?

In an older patient wtih T2DM, HFpEF, and other comorbidities, which class of medication is guideline-recommended?

 

Diabetes Type 2

Diabetes Drugs and Cardio-renal Protection: Trials and Indications

November 25, 2019
  • Veronica Hackethal, MD

Cardiovascular outcomes trials of diabetes drugs have led to label expansions and guideline endorsements. Do you recall the studies and the outcomes? Find out, here.

  • VIEW NOW >>

Dapagliflozin Approved to Reduce Risk of Hospitalization for Heart Failure in T2D

October 21, 2019
  • Grace Halsey

The SGLT2 inhibitor, on October 21, 2019 was granted a label expansion from FDA for the prevention of hospitalization for heart failure in patients with T2D. 

  • READ >>

Glycemic Control Improves with Motivational Texts

October 7, 2019
  • Grace Halsey

For people with type 2 diabetes, receiving motivational messages via mobile text was associated with reduced A1c vs patients who received usual care.

  • READ >>

PCPs are Missing Prediabetes, Survey Finds

September 11, 2019
  • Grace Halsey

Less than half of PCPs responding to a recent survey chose correct values for prediabetes screening tests and seemed unaware of other evidence-based recommendations for prediabetes.

  • READ >>

US Diabetes Treatment is Missing the Mark

September 9, 2019
  • Grace Halsey

US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.

  • READ >>
cost of diabetes, diabetes type 2, type 1 diabetes

Diabetes Drug Costs Force Patients to Cut Corners

August 21, 2019
  • Grace Halsey

About 25% of patients with diabetes report asking a physician for a cheaper drug. Skipping doses and pill splitting are tactics used to cut costs.

  • VIEW NOW >>

Treatment Intensification in Type 2 Diabetes: 3 Cases

July 18, 2019
  • Sudipa Sarkar, MD

When intensifying T2DM therapy to reach glycemic goals, newer agents target common comorbidities. Which would you choose in these 3 scenarios?

  • VIEW NOW >>
Type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors

After Metformin: Which Class Would you Choose?

July 10, 2019
  • Payal Kohli, MD

In this older patient with T2DM, HFpEF, and other comorbidities, which class of medication is most appropriate--and guideline-recommended?

  • VIEW NOW >>

The "Sweet Spot" in Type 2 Diabetes Management

July 1, 2019
  • Payal Kohli, MD

The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.

  • VIEW NOW >>

Novel Dual-mechanism Agent Acts on Diabetes, Metabolic Complications

June 25, 2019
  • Kenneth J. Bender, PharmD, MA

ADA 2019 ICYMI: Tirzepatide, a GIP and GLP-1 receptor agonist, reduces A1c and BMI as well as biomarkers of metabolic dysfunction in type 2 diabetes patients. Four studies reviewed.

  • READ >>

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Cystic Fibrosis
  • Kidney Disease
  • Hepatitis C
  • Headache and Migraine
  • COPD Management
There is currently no available content. Please check back soon.
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".